Analysis of Tumor-associated antigens (TAAs) in childhood melanoma4

14.06.2021 bis 14.06.2022

RNA based cancer vaccines can induce an immune response directed against tumor antigens in melanoma patients (1). The investigational drug FixVac (BNT111) targets four non-mutated, tumor-associated antigens that are expressed in adult melanoma. However, there is no data available regarding expression of these antigens in childhood melanoma. The goal of this study is to examine the expression of TAAs in childhood melanoma in the context of developing FixVac (BNT111) for the treatment of childhood melanomas.